Skip to main content
. Author manuscript; available in PMC: 2012 Dec 5.
Published in final edited form as: Leukemia. 2011 Sep 2;26(1):34–53. doi: 10.1038/leu.2011.197

Table 4.

Summary of α4 integrin antagonists tested in human clinical trials

Drug Company Class Disease Clinical trial status Reference
Bio-1211 Biogen/Merck LDV Asthma Phase II 261
IVL-745 Aventis LDV Asthma Phase II 262
TBC-4746 Encysive/Schering Plough LDV Asthma/MS Phase I 208
DW-908e Daiichi-Sankyp/Pharmacopeia LDV Asthma Phase I 263
R-411/Valetegrast Roche N-acyl phenylalanine Asthma Phase II 264
AJM-300 Ajinomoto N-acyl phenylalanine IBD Phase II 212, 213
SB-683699/Firategrast GlaxoSmithKliine N-acyl phenylalanine MS Phase II 208, 211
CDP323 UCB/Biogen N-acyl phenylalanine MS Phase II 207
Compound 14e Daiichi Sankyo N-acyl phenylalanine NA Phase I 214

Abbreviations: LDV, leucine–aspartic acid–valine; MS, multiple sclerosis; IBD, inflammatory bowel disease.